Literature DB >> 20847883

Recent Trends in Breast Cancer Incidence and Mortality in Germany.

Alexander Katalinic1, Ron Pritzkuleit, Annika Waldmann.   

Abstract

SUMMARY:
BACKGROUND: Breast cancer is the most common cancer among women in Germany with high public health impact. In the last decade rapid changes in risk factor patterns, early breast cancer detection, and therapy have taken place. Their effects on breast cancer epidemiology in Germany are described.
MATERIALS AND METHODS: A register-based survey using recent incidence data from German cancer registries was performed. Mortality data were provided by the Central Federal Statistical Office. We calculated age-standardized rates and 5- and 10-year trends.
RESULTS: Breast cancer incidence increased until the year 2002, thereafter a discreet decline occurred until 2005 (-6.8%). In the age group 50-59 years this reduction was most pronounced (-12%). Mortality declined from 1996/7 to 2004/5 by 19%, with the strongest effect in women younger than 55 years (approximately 30%). Regional patterns of breast cancer incidence and mortality revealed differences within Germany of greater than 30%.
CONCLUSION: Declining hormone replacement therapy prescription is the most likely factor to explain the drop in breast cancer incidence. The reduction in mortality might be caused by better therapy and enhanced early detection during the last decade. Differences in breast cancer incidence and mortality between Eastern and Western Germany give reason for further research and discussion.

Entities:  

Year:  2009        PMID: 20847883      PMCID: PMC2931064          DOI: 10.1159/000211526

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  16 in total

Review 1.  [Mammography screening in Germany].

Authors:  S Diekmann; F Diekmann
Journal:  Radiologe       Date:  2008-01       Impact factor: 0.635

2.  Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study.

Authors:  Adrianne Faber; Marcel L Bouvy; Linda Loskamp; Paul B van de Berg; Toine C G Egberts; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

3.  Benefit of screening mammography in women aged 40-49: a new meta-analysis of randomized controlled trials.

Authors:  R E Hendrick; R A Smith; J H Rutledge; C R Smart
Journal:  J Natl Cancer Inst Monogr       Date:  1997

4.  [Contributions of the epidemiological cancer registries to the evaluation of mammography screening in Germany].

Authors:  I Urbschat; J Kieschke; U Schlanstedt-Jahn; S von Gehlen; A Thiel; P Jensch
Journal:  Gesundheitswesen       Date:  2005-07

5.  Decline in hormone replacement prescription and fall in breast cancer incidence: an epidemiological discourse.

Authors:  Andreas Stang
Journal:  Dtsch Arztebl Int       Date:  2008-04-18       Impact factor: 5.594

6.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

7.  The decrease in breast-cancer incidence in 2003 in the United States.

Authors:  Peter M Ravdin; Kathleen A Cronin; Nadia Howlader; Christine D Berg; Rowan T Chlebowski; Eric J Feuer; Brenda K Edwards; Donald A Berry
Journal:  N Engl J Med       Date:  2007-04-19       Impact factor: 91.245

8.  Use of hormone replacement therapy, 1998-2007: sustained impact of the Women's Health Initiative findings.

Authors:  Barbara G Silverman; Ehud S Kokia
Journal:  Ann Pharmacother       Date:  2009-02-03       Impact factor: 3.154

9.  Breast cancer after use of estrogen plus progestin in postmenopausal women.

Authors:  Rowan T Chlebowski; Lewis H Kuller; Ross L Prentice; Marcia L Stefanick; JoAnn E Manson; Margery Gass; Aaron K Aragaki; Judith K Ockene; Dorothy S Lane; Gloria E Sarto; Aleksandar Rajkovic; Robert Schenken; Susan L Hendrix; Peter M Ravdin; Thomas E Rohan; Shagufta Yasmeen; Garnet Anderson
Journal:  N Engl J Med       Date:  2009-02-05       Impact factor: 91.245

10.  Decline in use of hormone therapy among postmenopausal women in the United Kingdom.

Authors:  Usha Menon; Matthew Burnell; Aarti Sharma; Aleksandra Gentry-Maharaj; Lindsay Fraser; Andy Ryan; Mahesh Parmar; Myra Hunter; Ian Jacobs
Journal:  Menopause       Date:  2007 May-Jun       Impact factor: 2.953

View more
  7 in total

1.  The Epidemiology and Aetiology of Female Breast Cancer.

Authors:  Andreas Stang; Rita K Schmutzler
Journal:  Breast Care (Basel)       Date:  2009-04-24       Impact factor: 2.860

2.  Is routine audiometric evaluation necessary in gynaecologic tumour patients undergoing chemotherapy?

Authors:  Ayotunde J Fasunla; Nadia Harbeck; Barbara Schmalfeld; Sabina Berktold; Christina Böhner; Walter Hundt; Petra Wolf; Silke Steinbach
Journal:  Breast Care (Basel)       Date:  2013-08       Impact factor: 2.860

3.  Epidemiology of Breast Cancer - Current Figures and Trends.

Authors:  N Eisemann; A Waldmann; A Katalinic
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-02       Impact factor: 2.915

4.  Hypo- vs. normofractionated radiation therapy in breast cancer: A patterns of care analysis in German speaking countries.

Authors:  M Mayinger; C Straube; D Habermehl; M N Duma; S E Combs
Journal:  Rep Pract Oncol Radiother       Date:  2020-07-28

5.  Cancer mortality in former East and West Germany: a story of unification?

Authors:  Daniel Medenwald; Dirk Vordermark; Christian T Dietzel
Journal:  BMC Cancer       Date:  2017-02-02       Impact factor: 4.430

6.  Prophylactic Acupuncture Treatment During Chemotherapy in Patients With Breast Cancer: Results of a Qualitative Study Nested in a Randomized Pragmatic Trial.

Authors:  Dr Med Barbara Stöckigt; Barbara Kirschbaum; Dr Med Martin Carstensen; Dr Med Claudia M Witt; Dr Med Benno Brinkhaus
Journal:  Integr Cancer Ther       Date:  2021 Jan-Dec       Impact factor: 3.279

7.  Breast cancer attributable costs in Germany: a top-down approach based on sickness funds data.

Authors:  Emil Victor Gruber; Stephanie Stock; Björn Stollenwerk
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.